CD274 and esophageal cancer: Immunohistochemistry (IHC) expression of PD-L1 is the most widely used biomarker for predicting the efficacy of esophageal cancer immunotherapy, and accurate and reliable PD-L1 testing is crucial for screening potential beneficiaries of immunotherapy.